ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Abpro Therapeutics on deck for IPO
biospectrumasia
April 16, 2018Co-lead candidates are ABP-100 and ABP-201, both tetravalent antibodies, meaning they bind to two different targets with two distinct binding sites per target.
Pharma Sources Insight January 2025
